v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 7,251 $ 8,836
Accounts receivable   268
Research and development tax credit receivable 807 610
Prepaid expenses and other current assets 1,082 811
Total current assets 9,140 10,525
Property, plant and equipment, net 388 455
Right-of-use assets, net 223 285
Other assets, non-current 6 7
Total assets 9,757 11,272
Current liabilities    
Accounts payable and accrued expenses 2,038 1,178
Lease liabilities, current 174 230
Other current liabilities 367 360
Total current liabilities 2,579 1,768
Lease liabilities, non-current 4 19
Warrant liability 619 1,372
Total liabilities 3,202 3,159
Commitments and contingencies (Note 7)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 3,592 and 13,765 shares issued and outstanding, at March 31, 2024 and December 31, 2023, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 1,379,750 and 889,668 shares issued and outstanding, at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital 112,007 104,757
Accumulated other comprehensive loss (1,596) (1,578)
Accumulated deficit (103,856) (95,066)
Total stockholders' equity 6,555 8,113
Total liabilities and stockholders' equity $ 9,757 $ 11,272

Source

HTML PDF
ZIP